AstraZeneca Resumes Vaccine Trials After Previously Pausing It for Safety
A week ago, it was reported that the trials for the Coronavirus Disease 2019 vaccine which was being developed by the pharmaceutical company AstraZeneca with the University of Oxford, has been put to hold due to a “suspected serious adverse reaction”. To allow a review of safety data, the company stated that the standard review process triggered a voluntary pause to vaccination across all global trials.
Following this update, just on September 12, 2020, the company announced that the clinical trials for AZD1222, AstraZeneca and Oxford’s vaccine, have already resumed in the UK.
According to them, the UK committee has concluded its investigations and recommended to the Medicines Health Regulatory Authority (MHRA) that it is safe to resume trials in the UK. Thus, MHRA has recently confirmed that it was safe to do so.
“AstraZeneca is committed to the safety of trial participants and the highest standards of conduct in clinical trials. The Company will continue to work with health authorities across the world and be guided as to when other clinical trials can resume to provide the vaccine broadly, equitably and at no profit during this pandemic.”
– AstraZeneca, September 12, 2020
Based on the press release published by the AstraZeneca, further medical information cannot be disclosed by their company and the University of Oxford. The participants and the investigators will, however, be updated with the relevant information.
For More News and Updates
See more news and updates by exploring our Baguio City Guide website and by liking and following our official Baguio City Guide Facebook page. For more content, you may also subscribe to our official Baguio City Guide YouTube channel.
Source: Science Alert, The New York Times, AstraZeneca
Related: AstraZeneca paused its Vaccine Trial
How do you feel about this?
